Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS) Read more
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer Read more
Bristol Myers Squibb Announces FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis Read more
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Read more
UCB announces FDA approval of ZILBRYSQ (zilucoplan) for the treatment of adults with generalized myasthenia gravis Read more
FDA Approves Pfizer’s BRAFTOVI + MEKTOVI for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Read more
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program Read more
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline Read more